Breaking News

Nexcella Starts NXC-201 Engineering Batches at U.S. CAR-T Manufacturing Site

Mark the first step in transferring existing CAR-T GMP manufacturing process to the U.S.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, started CAR-T NXC-201 engineering batches at its U.S. manufacturing site. These U.S. engineering batches will support the planned U.S. expansion of the company’s ongoing Phase 1b/2a NEXICART-1 (NCT04720313) study of its novel BCMA-targeted chimeric antigen receptor T (car-T) cell therapy NXC-201.  ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters